Form 4: Incyte Corp Director Paul J Clancy Acquires Shares in Compliance with Rule 10b5-1
SEC Form 4 Filing
Director Paul J Clancy acquired 358 shares of Incyte Corp common stock at $60.55 per share on March 31, 2025, under the company's Amended and Restated 2010 Stock Incentive Plan.
Summary
- On March 31, 2025, Paul J Clancy, a director of Incyte Corp, acquired 358 shares of common stock at a price of $60.55 per share.
- The acquisition was made under the Issuer's Amended and Restated 2010 Stock Incentive Plan.
- These shares were issued in lieu of quarterly director retainer fees, pursuant to an election by Clancy intended to comply with Rule 10b5-1.
- Following the transaction, Clancy beneficially owns 20,071 shares of Incyte Corp common stock, which includes 2,830 shares issuable pursuant to previously reported restricted stock units that have not vested.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports a routine transaction. The director's purchase could be seen as a positive signal, but it's a small transaction and part of a pre-arranged plan.
Positives
- The acquisition demonstrates the director's continued investment in the company.
- The use of Rule 10b5-1 indicates a pre-planned and transparent approach to stock transactions.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company directors and their investment decisions.
Comparison to Industry Standards
- Insider trading disclosures are standard practice for publicly listed companies like Incyte Corp.
- The use of Rule 10b5-1 plans is a common method for corporate insiders to trade company stock while avoiding accusations of insider trading.
- Comparable companies such as Gilead Sciences, Amgen, and Vertex Pharmaceuticals also have similar insider trading reporting requirements.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder confidence due to the director's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of transaction: Paul J Clancy acquired 358 shares of Incyte Corp common stock. |
| 04/02/2025 | Date of signature by Elizabeth Feeney, Attorney-In-Fact. |
Keywords
Incyte Corp, Director, Paul J Clancy, Stock Acquisition, Rule 10b5-1, Beneficial Ownership, Stock Incentive Plan, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.